Citations

Clear

4847 citation(s) found for "Tu, Eric".

Epidemiology of cutaneous sarcoidosis, 1976–2013: a population‐based study from Olmsted County, Minnesota
Ungprasert, Patompong , Wetter, David A. , Crowson, Cynthia S. , Matteson, Eric L.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 21, 2016 | Volume: 30 | Issue: 10 | Pages: 1799-1804

10.1111/jdv.13760 | PMID 27324138 Get It

AbstractBackgroundThe epidemiology of cutaneous sarcoidosis is not well‐characterized as only referral‐based studies are available.ObjectivesTo characterize the epidemiology of cutaneous sarcoidosis, with emphasis on annual incidence and clinical characteristics, from 1976 to 2013.MethodsInception cohorts of patients with incident isolated cutaneous sarcoidosis and incident systemic sarcoidosis with cutaneous involvement in 1976–2013 in Olmsted County, Minnesota, United States were identified based on comprehensive individual medical record review. Inclusion in the isolated cutaneous sarcoidosis cohort required physician diagnosis and skin biopsy showing non‐necrotizing granuloma. Inclusion in the systemic sarcoidosis with cutaneous involvement cohort required presence of systemic sarcoidosis and cutaneous lesions. Presence of systemic sarcoidosis was determined by physician diagnosis supported by histopathology of non‐necrotizing granuloma, characteristic radiologic features of intrathoracic sarcoidosis and exclusion of other granulomatous diseases. Cutaneous lesions were defined as either sarcoidosis‐specific or non‐specific.ResultsThere were 62 cases with sarcoidosis‐specific cutaneous lesions (36 cases of sarcoidosis‐specific cutaneous lesions and 26 cases of isolated cutaneous sarcoidosis) which corresponded to an incidence of 1.9 per 100 000 population. The female to male ratio was 2.1 : 1. Plaques, papules and subcutaneous nodules were the most commonly observed cutaneous lesions. There was no significant difference in cutaneous presentation between those who had isolated skin disease and those who had skin disease in association with systemic sarcoidosis. Prognosis of cutaneous sarcoidosis was favourable, as over 90% of patients had a good response to either glucocorticoids, hydroxychloroquine or tetracycline antibiotics. This study has a significant limitation, in that the studied population was predominantly Caucasians who generally have a lower prevalence of skin disease.ConclusionsThe incidence of sarcoidosis‐specific cutaneous lesions was about 1.9 per 100 000 population with female predominance. The cutaneous presentations were similar among those with and without systemic sarcoidosis.
Time Trends in the Incidence of Parkinson Disease
Savica, Rodolfo , Grossardt, Brandon R. , Bower, James H., Ahlskog, J. Eric , Rocca, Walter A. , Grossardt, Brandon R

Mayo Clinic

JAMA Neurology | June 20, 2016 | Volume: 73 | Issue: 8 | Pages: 981

10.1001/jamaneurol.2016.0947 | PMID 27323276 Get It

Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
You, Sungyong , Erho, Nicholas , Alshalalfa, Mohammed , Takhar, Mandeep, Ashab, Hussam Al-Deen, Karnes, R. Jeffrey , Klein, Eric A. , Den, Robert B. , Ross, Ashley E. , Schaeffer, Edward M. , Garraway, Isla P. , Freeman, Michael R. , Knudsen, Beatrice S. , Davicioni, Elai , Kim, Jayoung , Den, Robert B , Klein, Eric A

Mayo Clinic

Cancer Research | June 15, 2016 | Volume: 76 | Issue: 17 | Pages: 4948-4958

10.1158/0008-5472.can-16-0902 | PMID 27302169 Get It

Abstract Prostate cancer is a biologically heterogeneous disease with variable molecular alterations underlying cancer initiation and progression. Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed to improve prognostic accuracy and therapeutic outcomes. In this study, we computationally assembled a large virtual cohort (n = 1,321) of human prostate cancer transcriptome profiles from 38 distinct cohorts and, using pathway activation signatures of known relevance to prostate cancer, developed a novel classification system consisting of three distinct subtypes (named PCS1–3). We validated this subtyping scheme in 10 independent patient cohorts and 19 laboratory models of prostate cancer, including cell lines and genetically engineered mouse models. Analysis of subtype-specific gene expression patterns in independent datasets derived from luminal and basal cell models provides evidence that PCS1 and PCS2 tumors reflect luminal subtypes, while PCS3 represents a basal subtype. We show that PCS1 tumors progress more rapidly to metastatic disease in comparison with PCS2 or PCS3, including PSC1 tumors of low Gleason grade. To apply this finding clinically, we developed a 37-gene panel that accurately assigns individual tumors to one of the three PCS subtypes. This panel was also applied to circulating tumor cells (CTC) and provided evidence that PCS1 CTCs may reflect enzalutamide resistance. In summary, PCS subtyping may improve accuracy in predicting the likelihood of clinical progression and permit treatment stratification at early and late disease stages. Cancer Res; 76(17); 4948–58. ©2016 AACR.
Polymyalgia Rheumatica and Giant Cell Arteritis
Buttgereit, Frank , Dejaco, Christian , Matteson, Eric L. , Dasgupta, Bhaskar , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

JAMA | June 14, 2016 | Volume: 315 | Issue: 22 | Pages: 2442

10.1001/jama.2016.5444 | PMID 27299619 Get It

Molecular analysis of idiopathic subglottic stenosis for Mycobacterium species
Gelbard, Alexander , Katsantonis, Nicolas‐George, Mizuta, Masanobu , Newcomb, Dawn C. , Rotsinger, Joseph E. , Rousseau, Bernard , Daniero, James J. , Edell, Eric S. , Ekbom, Dale C. , Kasperbauer, Jan L. , Yang, Liying , Garrett, C. Gaelyn , Netterville, James L. , Wootten, Christopher T. , Francis, David O. , Stratton, Charles W. , Jenkins, Kevin M., McGregor, Tracy L., Gaddy, Jennifer A. , Drake, Wonder P. , Hillel, Alexander T. , Blackwell, Timothy S , Gelbard, Alexander

Mayo Clinic

The Laryngoscope | June 14, 2016 | Volume: 127 | Issue: 1 | Pages: 179-185

10.1002/lary.26097 | PMID 27295947 Get It

Objectives/HypothesisIdiopathic subglottic stenosis (iSGS) is an unexplained obstruction involving the lower laryngeal and upper tracheal airway. Persistent mucosal inflammation is a hallmark of the disease. Epithelial microbiota dysbiosis is found in other chronic inflammatory mucosal diseases; however, the relationship between tracheal microbiota composition and iSGS is unknown.Given the critical role for host defense at mucosal barriers, we analyzed tissue specimens from iSGS patients for the presence of microbial pathogens.MethodsUtilizing 30 human iSGS, 20 intubation‐related tracheal stenosis (iLTS), and 20 healthy control specimens, we applied molecular, immunohistochemical, electron microscopic, immunologic, and Sanger‐sequencing techniques.ResultsWith unbiased culture‐independent nucleic acid, protein, and immunologic approaches, we demonstrate that Mycobacterium species are uniquely associated with iSGS. Phylogenetic analysis of the mycobacterial virulence factor rpoB suggests that, rather than Mycobacterium tuberculosis, a variant member of the Mycobacterium tuberculosis complex or a closely related novel mycobacterium is present in iSGS specimens.ConclusionThese studies identify a novel pathogenic role for established large airway bacteria and provide new targets for future therapeutic intervention.Level of EvidenceNA Laryngoscope, 127:179–185, 2017
Idiopathic subglottic stenosis is associated with activation of the inflammatory IL‐17A/IL‐23 axis
Gelbard, Alexander , Katsantonis, Nicolas‐George, Mizuta, Masanobu , Newcomb, Dawn C. , Rotsinger, Joseph E. , Rousseau, Bernard , Daniero, James J. , Edell, Eric S. , Ekbom, Dale C. , Kasperbauer, Jan L. , Yang, Liying , Garrett, C. Gaelyn , Netterville, James L. , Wootten, Christopher T. , Francis, David O. , Stratton, Charles W. , Jenkins, Kevin M., McGregor, Tracy L., Gaddy, Jennifer A. , Drake, Wonder P. , Hillel, Alexander T. , Blackwell, Timothy S , Gelbard, Alexander

Mayo Clinic

The Laryngoscope | June 14, 2016 | Volume: 126 | Issue: 11 | Pages: No page available

10.1002/lary.26098 | PMID 27296163 Get It

Objectives/HypothesisIdiopathic subglottic stenosis (iSGS) is a rare and devastating extrathoracic obstruction involving the lower laryngeal and upper tracheal airway. It arises without known antecedent injury or associated disease process. Persistent mucosal inflammation and a localized fibrotic response are hallmarks of the disease. Despite the initial clinical description of iSGS more than 40 year ago, there have been no substantive investigations into the pathogenesis of this enigmatic and progressive airway obstruction. In these studies, we present the initial characterization of the molecular pathogenesis underlying the fibrosing phenotype of iSGS.MethodsUtilizing 20 human iSGS and healthy control specimens, we applied histologic, immunohistochemical, molecular, and immunologic techniques.ResultsWe demonstrate significant activation of the canonical IL‐23/IL‐17A pathway in the tracheal mucosa of iSGS patients, as well as identify γδ T cells as the primary cellular source of IL‐17A.ConclusionOur results suggest that aberrant mucosal immune activation is a component in of the pathogenesis of iSGS. Most critically, our work offers new targets for future therapeutic intervention.Level of EvidenceNA Laryngoscope, 126:E356–E361, 2016
Acute Kidney Injury After Intravenous Versus Intra-Arterial Contrast Material Administration in a Paired Cohort
Leake, Caleb B., McDonald, Robert J. , Gulati, Rajiv , Katzberg, Richard W. , Williamson, Eric E. , Kallmes, David F. , McDonald, Jennifer S.

Mayo Clinic

Investigative Radiology | June 14, 2016 | Volume: 51 | Issue: 12 | Pages: 804-809

10.1097/rli.0000000000000298 | PMID 27299579 Get It

Objectives The aim of this study was to determine whether intra-arterial administration of contrast material is associated with a higher risk of acute kidney injury (AKI) compared with that of intravenous (IV) administration in a cohort of patients that received both routes of administration. Materials and Methods All patients who received both a contrast-enhanced computed tomography (CT) and a diagnostic or interventional cardiac catheterization between 2000 and 2014 were identified. Patients who lacked sufficient preprocedure and postprocedure serum creatinine results, who were on preexisting renal dialysis, or who underwent additional contrast-enhanced procedures within 7 days of either procedure were excluded. The rate of AKI (serum creatinine ≥0.3 mg/dL or 50% above baseline) was compared after CT scan and cardiac catheterization using McNemar test. Results A total of 1969 patients met all study inclusion criteria. The rate of AKI after CT scan was similar to the rate after catheterization when examining all patients (9.9% CT vs 11% catheterization, P = 0.12). A similar rate of AKI after both procedures was observed regardless of procedure order, catheterization type, and patient baseline estimated glomerular filtration rate. Conclusions Intra-arterial administration of contrast material during cardiac catheterization had a similar risk of AKI as compared with that of CT scanning involving IV administration in a cohort of patients who underwent both procedures. These findings suggest that previously reported much higher rates of AKI after cardiac catheterization compared with that of IV contrast administration reflect higher baseline clinical risk factors for AKI in the former cohort compared with that in the latter.
Author response: Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain
He, Shuning , Gjini, Evisa , Groh, Eric D. de, Zhu, Shizhen , Look, A. Thomas , Mansour, Marc R. , Zimmerman, Mark W. , Ki, Dong Hyuk , Layden, Hillary M. , Akahane, Koshi , Pérez‐Atayde, Antonio R. , Epstein, Jonathan A.

Mayo Clinic

No container title available | June 9, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.14713.017 Get It

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Ali, Siraj M. , Hensing, Thomas A., Schrock, Alexa B. , Allen, Justin, Gowen, Kyle , He, Jie , Suh, James , Lipson, Doron , Elvin, Julia A. , Yelensky, Roman , Chmielecki, Juliann , Peled, Nir , Klempner, Samuel J. , Firozvi, Kashif, Frampton, Garrett M. , Molina, Julian R. , Menon, Smitha, Brahmer, Julie R. , MacMahon, Heber , Nowak, Jan A. , Ladanyi, Marc , Zakowski, Maureen F. , Fischbach, Neil, Stephens, Phil , Miller, Vincent A. , Wakelee, Heather A. , Ganesan, Shridar , Salgia, Ravi , Sanford, Eric M. , Kulkarni, Atul , Elvin, Julia A , Chalmers, Zachary Rockow , Ou, Sai‐Hong Ignatius , Zauderer, Marjorie G. , Ross, Jeffrey S , Klempner, Samuel J , Frampton, Garrett M

Mayo Clinic

The Oncologist | May 31, 2016 | Volume: 21 | Issue: 6 | Pages: 762-770

10.1634/theoncologist.2015-0497 | PMID 27245569 Get It

Abstract Introduction. For patients with non-small cell lung cancer (NSCLC) to benefit from ALK inhibitors, sensitive and specific detection of ALK genomic rearrangements is needed. ALK break-apart fluorescence in situ hybridization (FISH) is the U.S. Food and Drug Administration approved and standard-of-care diagnostic assay, but identification of ALK rearrangements by other methods reported in NSCLC cases that tested negative for ALK rearrangements by FISH suggests a significant false-negative rate. We report here a large series of NSCLC cases assayed by hybrid-capture-based comprehensive genomic profiling (CGP) in the course of clinical care. Materials and Methods. Hybrid-capture-based CGP using next-generation sequencing was performed in the course of clinical care of 1,070 patients with advanced lung cancer. Each tumor sample was evaluated for all classes of genomic alterations, including base-pair substitutions, insertions/deletions, copy number alterations and rearrangements, as well as fusions/rearrangements. Results. A total of 47 patients (4.4%) were found to harbor ALK rearrangements, of whom 41 had an EML4-ALK fusion, and 6 had other fusion partners, including 3 previously unreported rearrangement events: EIF2AK-ALK, PPM1B-ALK, and PRKAR1A-ALK. Of 41 patients harboring ALK rearrangements, 31 had prior FISH testing results available. Of these, 20 were ALK FISH positive, and 11 (35%) were ALK FISH negative. Of the latter 11 patients, 9 received crizotinib based on the CGP results, and 7 achieved a response with median duration of 17 months. Conclusion. Comprehensive genomic profiling detected canonical ALK rearrangements and ALK rearrangements with noncanonical fusion partners in a subset of patients with NSCLC with previously negative ALK FISH results. In this series, such patients had durable responses to ALK inhibitors, comparable to historical response rates for ALK FISH-positive cases.